Higher frequency of secretor phenotype in O blood group – its benefits in prevention and/or treatment of some diseases

Mohamad Salih Jaff

Pathology Department, Hawler Medical University (Formerly Salahaddin University), Erbil, Kurdistan Region, Iraq

Abstract: ABO blood groups and secretor status are important in clinical and forensic medicine and in relation to some diseases. There are geographic and racial differences in their frequencies, but the frequency of secretor status in different ABO blood group systems has not been determined yet. Therefore, the aim of this study was mainly to determine this point. Blood and saliva from 762 randomly selected apparently healthy adult individuals (480 men and 282 women) were examined to determine their ABO and Rhesus blood groups by standard conventional methods, and their secretor status by using Lewis blood grouping and/or hemagglutination inhibition test of saliva. Results showed that 76.1% of the study population were ABH blood group antigens secretors and 23.9% were nonsecretors. The frequencies of secretor status in different ABO blood groups were 70.1% in group A, 67.8% in group B, 67.9% in group AB, and 88.3% in group O. In conclusion, blood group O individuals have significantly higher frequency of secretor status than non-O blood group individuals. This finding would be beneficial to them, protecting them, at least partially, from certain malignancies or allowing them to have less aggressive disease, and this finding might be useful in enhancing further studies and research in this direction.

Keywords: blood group O, ABO blood groups, secretor phenotype, frequency, malignancies, prevention and/or treatment

Introduction

In 1930, it was found that individuals could be classified as ‘secretors’ and ‘nonsecretors’ according to their ability to secrete ABO blood group antigens in saliva.¹ ABO blood group antigens (A, B, and H), in addition to their presence on blood cells and platelets, are also present on other tissue cells and are variably expressed through body fluids, such as saliva, tears, semen, urine, gastric juice, and breast milk, depending on whether the individual possesses the secretor gene or not, the inherited A, B, O genes, and Lewis blood group system.²

In addition to ABO blood group applications in blood transfusion and forensic medicine, numerous studies have found strong relations between individuals’ susceptibilities to some diseases and their ABO blood groups,³ as well as their secretor status.⁴

The secretor gene encodes for enzymes (glycosyltransferases), which become active in mucin-secreting cells like goblet and mucous cells of mucous membranes and different glands, resulting in the secretion of the corresponding blood group antigens in the body fluids.⁵ H antigen that is present on the cells of individuals with O blood group is the base for A and B antigens, but A and B antigens differ only in their added terminal sugars, which are controlled by specific enzymes called transferase enzymes. These enzymes are under the control of inherited genes, which are A, B, H (*FUT1*) genes and secretor

Correspondence: Mohamad Salih Jaff
Pathology Department, Hawler Medical University (Formerly Salahaddin University), P.O.B. 0845/14, Engineering College Houses, No. 25, Kirkuk Street, Erbil, Kurdistan Region, Iraq
Tel +00964 0750 4777683
Email msjaff@yahoo.com

(*FUT2*) genes.⁶ H (*FUT1*) and secretor (*FUT2*) genes are separate but closely linked. Lewis blood group phenotypes are also important in determining the secretor status of an individual, as Lewis genes (*FUT3*) are closely linked to secretor (*FUT2*) and H (*FUT1*) genes.^{7,8} Subjects are either Lewis negative or Lewis positive. In Lewis-negative individuals, the secretor genotype does not affect the Lewis phenotype. However, in Lewis-positive individuals, the secretor genotype generates either the nonsecretor phenotype Le(a+b−) or the secretor phenotype Le(a−b+), or the partial secretor genotype, which gives rise to a transient Le(a+b+) phenotype.⁹ Therefore, practically, there are only three Lewis phenotypes: Le(a+b−), Le(a−b+), and Le(a−b−).

The frequencies of different Lewis-secretor phenotypes vary markedly among different ethnic populations.¹⁰ It is generally known that about 80% of the world's population are secretors of ABH antigens and only 20% are nonsecretors but with some racial differences.⁸ One of the studies in our region showed that 78% of Kurds are secretors and 22% of them are nonsecretors.¹¹

Because most secretors have a Lewis blood group of Le(a−b+) phenotype and most nonsecretors have a Lewis blood group of Le(a+b−) phenotype, Lewis blood grouping is used to detect the secretor status of most of the population. Only a minority of the population (5%–10%)^{12,13} have Le(a−b−) phenotype, ie, Lewis double negative (LDN). For these people, as the standard Lewis blood grouping cannot be used to determine their secretor status, saliva testing by the standard hemagglutination inhibition test is used.¹⁴

To the best of our knowledge, there are no reports on the incidence of secretor status in different ABO blood groups (A, B, AB, and O), and to investigate this point we planned this study.

Materials and methods

Seven hundred and sixty-two apparently healthy unrelated adults (480 men and 282 women) were randomly selected and asked to volunteer for this study, after they were informed about its aim. This study was carried out in Hawler Teaching Hospital Laboratory, Erbil, Kurdistan Region, Iraq, in the period between January 2008 and May 2010.

From each individual, 3 mL of blood was taken into sterile plain tubes. Subjects were informed to rinse their mouth with water prior to saliva collection. After chewing a piece of paraffin wax, to stimulate secretion of saliva, 5 mL of saliva was collected in sterile plain glass tubes. Saliva samples were tested within 2 h of collection.

ABO and Rhesus blood grouping was performed on saline-washed red blood cells using commercial antisera kits: monoclonal anti-A, anti-B antisera (Plasmatec Laboratory Products Ltd., Bridport, Dorset, UK), and monoclonal anti-H antiserum (Seraclone, Biotest, Dreieich, Germany) by the standard conventional hemagglutination technique.

Lewis blood group phenotype was also performed on the saline-washed RBCs by the standard hemagglutination technique using monoclonal anti-Le(a) and anti-Le(b) (Lorne Labs, Reading, Berkshire, UK) according to the manufacturer's instructions. Individuals with Le(a−b+) were assigned as secretors, those with Le(a+b−) were assigned as nonsecretors, and those with Le(a−b−), ie, LDN, were assigned unknown secretor status, for whom saliva was used to determine their secretor status by the standard hemagglutination inhibition test.

Statistical analysis was performed using Windows software, Microsoft Office Excel 2003. χ^2 tests and *t*-test were used to determine the significance of the influence of sex, Rh type, and different ABO blood groups on the frequency of secretor status among the study population. *P* values <0.05 were regarded as significant.

Results

The total number of participants in this study was 762 (480 men and 282 women). Their age ranged between 19 and 45 years with a median of 34 years. The frequencies of Lewis blood group phenotypes Le(a+b−), Le(a−b+), and Le(a−b−) are shown in Table 1. Saliva test was done on 84 individuals with Le(a−b−) phenotype and showed that 60 (71%) of them were secretors and 24 (29%) were nonsecretors. Secretor and nonsecretor status formed 76.1% and 23.9% of the study population, respectively. In men, 75.6% were secretors and 24.4% were nonsecretors, while in women 74.1% were secretors and 25.9% were nonsecretors (Table 2). In Rh(D)-positive individuals, 76% were secretors and 24% were nonsecretors, while in Rh(D)-negative individuals 77% were secretors and 23% were nonsecretors (Table 3). Statistically, no significant differences were found in the secretor status between men and women (*P* > 0.05) as well

Table 1 Frequency of Lewis blood group phenotype in the study population

Lewis phenotype	Secretors		Nonsecretors		Total	
Le(a+b−)	0	0%	158	100%	158	20.7%
Le(a−b+)	520	100%	0	0%	520	68.3%
Le(a−b−)	60	71.4%	24	28.6%	84	11.0%
Total	580	76.1	182	23.9	762	100%

Table 2 Distribution and comparison of secretor status prevalence in men and women

Gender	Male		Female		Total		P
Secretors	368	75.6%	212	74.1%	580	76.1%	>0.05
Nonsecretors	112	24.4%	70	25.9%	182	23.9%	–
Total	480	36.0%	282	37.0%	762	100%	–

as between Rh(D)-positive and Rh(D)-negative individuals ($P > 0.05$).

The distribution of ABO blood groups in the study population and the incidence of secretor status in different ABO blood groups are shown separately in Table 4. There was a highly significant increase in the incidence of secretor status in O blood group individuals when compared with A, B, and AB blood group individuals separately ($P < 0.0001$, $P < 0.0001$, $P = 0.0003$, respectively) and collectively ($P < 0.0001$). However, there were no significant differences in the incidence of secretor status in A, B, and AB blood groups when compared with each other ($P > 0.05$ for all comparisons) (Table 5).

Discussion

The incidence of secretor status in men and women and in Rh(D) group was in concordance with our previous study¹¹ and similar to many other studies.¹⁵ This significant increased incidence of secretor status in blood group O individuals in this study was not, to the best of our knowledge, recorded in the literature reviewed. This may at least, to some extent, explain the low incidence of certain diseases in blood group O individuals. Many published data from large cohort studies from different parts of the world suggest low incidence of many malignancies¹⁶ in group O compared with group A, eg, gastric carcinoma,¹⁷ oral cancerous lesions,^{18,19} lung,^{20,21} colon,²² ovarian cancer,²³ pancreatic carcinoma,^{24,25} prostatic carcinoma,²⁶ bladder cancer,²⁷ breast cancer,²⁸ and acute leukaemia.²⁹

Blood group O also appears to exert a protective effect by preventing the growth and spread of tumors and being associated with longer survival times in cancer patients.³⁰ The following will correlate our finding to, and might explain, the above finding. Thomsen-Friedenreich antigen

Table 3 Distribution and comparison of secretor status frequency in Rh(D)-positive and Rh(D)-negative individuals

Rhesus type	Rh-positive		Rh-negative		Total		P
Secretors	532	76%	48	77%	580	76.1%	>0.05
Nonsecretors	168	24%	14	23%	182	23.9%	–
Total	700	91.8%	62	8.1%	762	100%	–

Table 4 Frequency of secretor status in A, B, AB, and O blood group individuals

Blood group	Secretors		Nonsecretors		Total	
A	171	70.1%	73	29.9%	244	32.0%
B	124	67.8%	59	32.2%	183	24.0%
AB	36	67.9%	17	32.1%	53	7.0%
O	249	88.3%	33	11.7%	282	37.0%
Total	580	75.1%	182	23.9%	762	100%

(TF), which was discovered in the late 1920s,³¹ is the core disaccharide structure of ABO blood group (H) substance. It is cryptic on cell membranes of various normal cells, including epithelial cells, red blood cells, and lymphocytes. During carcinogenesis, it appears with several other different tumor-associated glycol antigens. It is expressed in many carcinomas, including those of the breast, colon, bladder, and prostate (pan-carcinoma marker), and becomes immunoreactive.³²

It has been postulated that TF has a role in adhesion and metastasis through tumor–endothelial-cell interactions, which is the key role in cancer metastasis,³³ and through binding ligands such as galectins or other lectins³⁴ in sites of metastatic tumor growth, ie, in the vascular endothelium, liver, bone marrow, and lymph nodes.³⁵ Due to antigenic similarity of TF to A antigen, blood group A individuals have the least aggressive humoral immune response against the TF than group O individuals, so it might be readily confused by the immune system of blood group A individuals.³²

Humans normally possess natural anti-TF antibodies (IgM), which are commonly induced in the gut, as many gram-negative organisms carry TF antigen, and people recovering from *Escherichia coli* enteritis and after infection with *Helicobacter pylori* apparently have higher levels of anti-TF antibodies.³⁶

Table 5 Comparison of blood group O secretor status prevalence with A, B, and AB blood groups separately and collectively

Blood groups, secretors/totals (%)	A (171/244) (70.1%)	B (124/183) (67.8%)	AB (36/53) (67.9%)	A + B + AB (331/480) (69.0%)
A (171/244) (70.1%)	–	$P = 0.074$	$P = 0.122$	$P = 0.065$
B (124/183) (67.8%)	$P = 0.074$	–	$P = 0.133$	$P = 0.071$
AB (36/53) (67.9%)	$P = 0.122$	$P = 0.133$	–	$P = 0.122$
O (249/282) (88.3%)	$P < 0.0001$	$P < 0.0001$	$P = 0.00031$	$P < 0.0001$

Interestingly, these bacteria grow more readily in blood group O individuals and secretors than non-O individuals, which means that they have more natural anti-TF IgM and IgG antibody production and probably are less susceptible to cancer or have less aggressive disease.³⁷ Higher levels of naturally occurring anti-TF antibody also appear to confer better prognosis.³⁸ Studies have also shown that secretors have the highest natural anti-TF IgM level irrespective of ABO phenotype.

Passive transfer of an anti-TF-Ag monoclonal antibody in animal experimental trials has significantly resulted in extending the median survival time of animals bearing metastatic 4T1 breast tumors and caused more than 50% inhibition of lung metastasis.³⁹

This means that individuals with O blood group, secretors, and postinfection with *E. coli* are strong responders of anti-TF antibody production together or independently, whether they are normal or cancer patients.

Von Willebrand factor (vWf) serves as an adhesive link between platelets and the endothelium. Several reports have demonstrated increased vWf antigen levels in the plasma of patients with ovarian, bladder, and colon cancers, with increased vWf antigen correlating with more metastasis and poor prognosis.⁴⁰

In fact, secretor genetics appears to interact with ABO genetics to influence the plasma levels of vWf, with non-secretors and non-O blood groups having the highest vWf concentrations, and the group O secretors having the lowest concentration of vWf:Ag and VIII:Ag.⁴¹

All these findings, collectively, lead us to the hypothesis that these tumors have more chance to thrive in A blood group patients and be more aggressive than in O blood group patients. In addition to the contribution of the above findings to the explanation of less aggressiveness of these malignancies in O blood group patients, it might also contribute to the explanation of the association of blood group O with other diseases.

In conclusion, blood group O individuals have significantly higher incidence of secretor status than non-O blood group individuals. Therefore, it is speculated that with the help of this finding and the above information from other studies, blood group O individuals with higher natural anti-TF IgM, lower levels of vWf, and higher susceptibility to infection by *H. pylori* and gram-negative intestinal flora are benefited and protected, at least partially, from certain malignancies or have less aggressive diseases. Also, we might be able to speculate that this finding might be useful in enhancing further studies and research in this direction.

Acknowledgments

The author would like to thank the staff of Hawler Teaching Hospital Laboratory, Erbil, Kurdistan Region, Iraq, for their cooperation during the laboratory work.

Disclosure

The author is the principal investigator and takes primary responsibility for the paper, as he was in charge of sample collection, performed the laboratory work, and wrote the paper.

References

1. Watkins WM. The ABO blood group system: historical background. *Transfus Med*. 2001;11(4):243–265.
2. Henry SM. The biosynthetic pathway for blood group related glycoconjugates in the human gastrointestinal tract; a map of pathogen receptors and insights into ABO. Paper Presented at NZIMLS Annual Scientific Meeting; 2001; Auckland, New Zealand.
3. Jaff MS, O'Brian DS. Excess of blood group B in primary myelofibrosis. *Vox Sang*. 1987;52(3):250–253.
4. D'Adamo PJ, Kelly GS. Metabolic and immunologic consequences of ABH secretor and Lewis subtype status. *Altern Med Rev*. 2001;6(4):390–405.
5. Slomiany BL, Slomiany A. ABH-blood-group antigens and glycolipid of human saliva. *Eur J Biochem*. 1978;85(1):249–254.
6. Greenwell P. Blood group antigens: molecules seeking a function? *Glycoconj J*. 1997;14(2):159–173.
7. Henry SM. Review: phenotyping for Lewis and secretor histo-blood group antigens. *Immunohaematology*. 1996;12:51–61.
8. Daniels G. *Human Blood Groups*. 2nd ed. Oxford (UK): Blackwell Science; 2002:7–70.
9. Henry S, Oriol R, Samuelsson B. Lewis histo-blood group system and associated secretory phenotypes. *Vox Sang*. 1995;69(3):166–182.
10. Henry S, Benny A, Woodsfield D. Investigation of Lewis phenotypes in Polynesians: evidence for a weak secretor phenotype. *Vox Sang*. 1990;58(1):61–66.
11. Jaff MS, Bilbas FAH. Frequency of the ABH blood group antigen secretors among kurds. *Zanco J Med Sci*. 2007;11(2):15–19.
12. Race RR, Sanger R. *Blood Groups in Man*. 6th ed. Oxford (UK): Blackwell; 1975:323–349.
13. Meeran K, Bloom SR. Lewis phenotypes, insulin resistance, and risk of ischemic heart disease (editorial). *Br Heart J*. 1994;71(4):305–306.
14. Harmening DM. *Modern Blood Banking and Transfusion Practices*. 4th ed. Philadelphia (PA): F.A. Davis Company; 1999:90–158.
15. de Mattos LC, Cintra JR, Sanches FE, Alves da Silva Rde C, Ruiz MA, Moreira HW. ABO, Lewis, secretor and non-secretor phenotypes in patients infected or uninfected by the *Helicobacter pylori* bacillus. *Sao Paulo Med J*. 2002;120(2):55–58.
16. Garratty G. Blood groups and disease: a historical perspective. *Transfus Med Rev*. 2000;14(4):291–301.
17. Sharara AI, Abdul-Baki H, El-Hajj I, Kreidieh N, Kfoury Baz EM. Association of gastroduodenal disease phenotype with ABO blood group and helicobacter pylori virulence-specific serotypes. *Dig Liver Dis*. 2006;38(11):829–833.
18. Campi C, Escovich L, Valdés V, et al. Secretor status and ABH antigens expression in patients with oral lesions. *Med Oral Patol Oral Cir Bucal*. 2007;12(6):E431–E434.
19. Dabelsteen E, Gao S. ABO blood-group antigens in oral cancer. *J Dent Res*. 2005;84(1):21–28.
20. Roots I, Drakoulis N, Ploch M, et al. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. *Klin Wochenschr*. 1988;66 Suppl 11: 87–97.

21. Roberts TE, Hasleton P, Swindell R, Lawson R. Blood groups and lung cancer. *Br J Cancer*. 1988;58(2):278.
22. Fujitani N, Liu Y, Toda S, Shirouzu K, Okamura T, Kimura H. Expression of H type 1 antigen of ABO histo-blood group in normal colon and aberrant expressions of H type 2 and H type 3/4 antigens in colon cancer. *Glycoconj J*. 2000;17(5):331–338.
23. Henderson J, Seagroatt V, Goldacre M. Ovarian cancer and ABO blood groups. *J Epidemiol Community Health*. 1993;47(4):287–289.
24. Vioque J, Walker AM. Pancreatic cancer and ABO blood types: a study of cases and controls. *Med Clin (Barc)*. 1991;96(20):761–764.
25. Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the Pancreatic Cancer Cohort Consortium. *Cancer Res*. 2009;70(3):1015–1023.
26. Oishi K, Okada K, Yoshida O, et al. Case-control study of prostatic cancer in Kyoto, Japan: demographic and some lifestyle risk factors. *Prostate*. 1989;14(2):117–122.
27. Nakata S, Sato J, Ohtake N, Imai K, Yamanaka H. Epidemiological study of risk factors for bladder cancer. *Hinyokika Kyo*. 1995;41(12):969–977.
28. Anderson DE, Haas C. Blood type A and familial breast cancer. *Cancer*. 1984;54(9):1845–1849.
29. Janardhana V, Propert DN, Green RE. ABO blood groups in hematologic malignancies. *Cancer Genet Cytogenet*. 1991;51(1):113–120.
30. Beckman L, Angqvist KA. On the mechanism behind the association between ABO blood groups and gastric carcinoma. *Hum Hered*. 1987;37(3):140–143.
31. Dippold W, Steinborn A, Meyer zum Buschenfelde KH. The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule. *Environ Health Perspect*. 1990;88:255–257.
32. Springer GF. T and Tn, general carcinoma autoantigens. *Science*. 1984;224(4654):1198–1206.
33. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. *Nat Med*. 2000;6(1):100–102.
34. Avichezer D, Springer GF, Schechter B, Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. *Int J Cancer*. 1997;72(1):119–127. Erratum appears in *Int J Cancer*. 1997;72(5):918.
35. Choufani G, Nagy N, Saussez S, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. *Cancer*. 1999;86(11):2353–2363.
36. Black RE, Levine MM, Clements ML, Hughes T, O'Donnell S. Association between O blood group and occurrence and severity of diarrhoea due to *Escherichia coli*. *Trans R Soc Trop Med Hyg*. 1987;81(1):120–128.
37. Kurtenkov O, Klaamas K, Miljukhina L. The lower level of natural anti-Thomsen-Friedenreich antigen (TFA) agglutinins in sera of patients with gastric cancer related to ABO(H) blood-group phenotype. *Int J Cancer*. 1995;60(6):781–785.
38. Hansson LE, Nyrén O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. *N Engl J Med*. 1996;335(4):242–249.
39. Rittenhouse-Olson K. JAA-F11 extending the life of mice with breast cancer. *Expert Opin Biol Ther*. 2007;7(7):923–928.
40. Wang WS, Lin JK, Lin TC, et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. *World J Gastroenterol*. 2005;11(14):2166–2170.
41. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. *Br J Haematol*. 2002;116(2):350–356.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-nanomedicine-journal>

Dovepress

Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.